H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Ocugen (OCGN) to $8 from $7 and keeps a Buy rating on the shares. The firm says OCU410 continues to show efficacy in geographic atrophy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN: